- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Ulf Jönsson, former Biacore CEO, and Jim Richey, CEO Auguron, to join Plexera Board
Lumera Corporation (NASDAQ: LMRA), a leader in the emerging field of nanotechnology, announced today that Ulf Jönsson, Ph.D., former CEO of Biacore (now GE Healthcare), and Jim Richey, CEO of Auguron Biosciences, Inc., have joined the Board of Directors of its wholly owned subsidiary, Plexera Bioscience LLC.
"We are extremely pleased that Ulf and Jim have accepted to come onto the Plexera Board. Their breadth of experience, in particular with the use of Surface Plasmon Resonance in bio-analytical instrumentation, and history of achievement in the life sciences tool markets will undoubtedly allow them to make an immediate impact on the success of our company," said Joe Vallner, Chairman and Chief Executive Officer of Plexera.
Dr. Jönsson has a distinguished career spanning more than 20 years as an executive in the life science supply industry. Most notably, he was one of the three founders of Biacore AB starting in 1984 as a research department within Pharmacia Fine Chemicals. In 1987 this research was transferred into a wholly owned subsidiary, Pharmacia Biosensor AB, which became Biacore AB in 1996. Biacore was subsequently acquired by GE Healthcare in 2006 for approximately $390 million. Dr. Jönsson was CEO at Biacore from 2000 until 2004. He holds a Ph.D. in applied physics from the University of Linköping in Sweden.
"Having spent the better part of my career in developing and commercializing bio-analytical instrumentation, I have a real appreciation for the achievements that Plexera have introduced in their ProteomicProcessor™. I look forward to seeing this product's success and to seeing Plexera become an industry leader," said Jönsson.
Mr. Richey is co-founder, President and CEO of Auguron Biosciences, a protein array technology-based molecular diagnostics company spun out of Harvard Medical School. He has more than 25 years of experience in sales and marketing operations in the United States, Europe and Japan. He has held senior executive positions in numerous rapid growth biotechnology success stories including LJL BioSystems (acquired by Molecular Devices), PerSeptive BioSystems (acquired by Applied Biosystems, now Applera), Pharmacia Biosensor (acquired by GE Healthcare), and Pharmacia Biotech (acquired by Amersham and in turn by GE Healthcare).
"I've had the opportunity to work with the Plexera team off and on during the past two years and am impressed with the progress they have made. Their ingenious approach using SPR to create a high throughput research method in proteomics is sure to make its mark in the industry and propel Plexera to an industry leader with innovative solutions," said Richey.
About Lumera Corporation
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the communications/computing industries and for the bioscience industry through its wholly-owned subsidiary, Plexera Bioscience LLC. Both of these represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit http://www.lumera.com .
Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.
For more information, please click here
Hélène F. Jaillet, Ph.D
The Summit Group Communications
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Graphenea celebrates fifth anniversary April 27th, 2015
Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015
Nanion Technologies Appoints James Costantin as Director of Customer Relations: Nanion is pleased to announce the appointment of Dr. James Costantin as Director of Customer Relations at Nanion Technologies Inc. March 31st, 2015